JP Morgan Chase’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-13
| Closed | -$50 | – | 7850 |
|
|
2024
Q3 | $50 | Hold |
13
| – | – | ﹤0.01% | 7124 |
|
|
2024
Q2 | $30 | Sell |
13
-28
| -68% | -$72 | ﹤0.01% | 7114 |
|
|
2024
Q1 | $116 | Buy |
41
+3
| +8% | +$9 | ﹤0.01% | 6882 |
|
|
2023
Q4 | $119 | Buy |
38
+3
| +9% | +$10 | ﹤0.01% | 7104 |
|
|
2023
Q3 | $116 | Buy |
35
+15
| +75% | +$47 | ﹤0.01% | 6895 |
|
|
2023
Q2 | $66 | Hold |
20
| – | – | ﹤0.01% | 6726 |
|
|
2023
Q1 | $0 | Hold |
20
| – | – | ﹤0.01% | 7327 |
|
|
2022
Q4 | $0 | Sell |
20
-9
| -31% | -$59 | ﹤0.01% | 7098 |
|
|
2022
Q3 | $0 | Buy |
+29
| New | +$241 | ﹤0.01% | 6942 |
|
|
2021
Q1 | – | Sell |
-10
| Closed | – | – | 6425 |
|
|
2020
Q4 | $0 | Buy |
+10
| New | +$172 | ﹤0.01% | 5995 |
|
|
2019
Q3 | – | Sell |
-295
| Closed | -$4K | – | 6010 |
|
|
2019
Q2 | $4K | Sell |
295
-29,674
| -99% | -$448K | ﹤0.01% | 5655 |
|
|
2019
Q1 | $521K | Sell |
29,969
-75,642
| -72% | -$1.13M | ﹤0.01% | 4190 |
|
|
2018
Q4 | $1.44M | Sell |
105,611
-22,930
| -18% | -$404K | ﹤0.01% | 3511 |
|
|
2018
Q3 | $2.77M | Buy |
128,541
+76,850
| +149% | +$2.34M | ﹤0.01% | 3230 |
|
|
2018
Q2 | $2.21M | Sell |
51,691
-3,128
| -6% | -$143K | ﹤0.01% | 3343 |
|
|
2018
Q1 | $3.58M | Buy |
54,819
+54,022
| +6,778% | +$3.83M | ﹤0.01% | 2847 |
|
|
2017
Q4 | $58K | Buy |
797
+725
| +1,007% | +$60K | ﹤0.01% | 4850 |
|
|
2017
Q3 | $6K | Buy |
72
+10
| +16% | +$767 | ﹤0.01% | 4783 |
|
|
2017
Q2 | $4K | Sell |
62
-79
| -56% | -$9.78K | ﹤0.01% | 4789 |
|
|
2017
Q1 | $30K | Buy |
141
+94
| +200% | +$13.4K | ﹤0.01% | 4643 |
|
|
2016
Q4 | $4K | Buy |
+47
| New | +$5.3K | ﹤0.01% | 4888 |
|
|
2016
Q1 | – | Sell |
-1
| Closed | – | – | 4995 |
|
|
2015
Q4 | $0 | Buy |
+1
| New | +$326 | ﹤0.01% | 4828 |
|
JP Morgan Chase's LUMO Position: Q4 2024 in Review
JP Morgan Chase sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 13 shares — an estimated $50 sold.
JP Morgan Chase first reported a position in LUMO in Q4 2015 and held it in 22 quarters. The position peaked at $3.58M in Q1 2018. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- JP Morgan Chase reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- JP Morgan Chase sold 13 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $50.
- JP Morgan Chase first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2015 and held it in 22 quarters.
- JP Morgan Chase's Lumos Pharma, Inc. Common Stock position peaked at $3.58M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.